All In Biotech

Drug Trial Radar · NCT03190330

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Jun 26, 2019

Primary completion

May 3, 2023

Study completion May 3, 2023

Sponsor

Lead sponsor
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the post-marketing safety of ImbruvicaTM (ibrutinib capsule 140 milligram \[mg\]) under actual conditions of use, and to understand the incidence of adverse events (AEs) (serious and non-serious AEs).

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Mantle-Cell

Interventions

  • Ibrutinib 420 mgDrug

    Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.

  • Ibrutinib 560 mgDrug

    Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)
  2. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Avron Hospitals Pvt. Ltd

    Ahmedabad, India

  • Post Graduate Institute of Medical Education And Research PGIMER

    Chandigarh, India

  • Basavatarakam Indo-American Hospital

    Hyderabad, India

  • Bhagwan Mahaveer Cancer Hospital & Research Centre

    Jaipur, India

  • Cytecare Hospitals Pvt. Ltd

    Karnataka, India

  • Apollo Multispeciality Hospital Ltd

    Kolkata, India

  • Tata Medical Center

    Kolkata, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, India

  • Deenanath Mangeshkar Hospital and Research Centre

    Pune, India

  • Noble Hospital Pvt Ltd

    Pune, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.